Undisclosed next gen CAR-T / Pell Bio-Med Techno - LARVOL DELTA

Pell Biomedical was listed on the Innovation Board, with an underwriting price of 98 yuan, and the second phase clinical trial of lymphoma is completed by the end of the year. [Google translation] (stock.yahoo) - "In addition, Pell Biomedical has applied its self-developed and patented 'new generation multi-chain CAR-T technology platform' to develop towards the treatment of solid cancers. It has successfully confirmed its excellent results in eliminating ovarian cancer in animal experiments. It is expected to apply for an investigational new drug (IND) before 2025 and start clinical trials...Taiwan Cell Manufacturing Co., Ltd....has completed the design of the PIC/S GMP plant for cell genetic drugs to be built in Zhubei Biomedical Park at the end of 2023. It is planned to be contracted for construction in Q1 of 2024 and is expected to be completed in 2025. And after passing the GMP certification review, it can be connected to the production and manufacturing of GMP-grade preparations of CAR-T products that Pell Biomedical has obtained the new drug subsidy license."

Commercial • IND • Patent • Oncology • Solid Tumor